The Peripheral Nerve Injury Market Size (7MM) was ~USD 2.4 Billion in 2023, it is projected to grow by 2034, estimates DelveInsight

(Albany, USA) DelveInsight's "Peripheral Nerve Injury Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Peripheral Nerve Injury, historical and forecasted epidemiology as well as the Peripheral Nerve Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Explore In-depth insights into the evolving Peripheral Nerve Injury Market. Download sample report @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Peripheral Nerve Injury Market Report
• In the 7MM, the US accounted for the highest number of cases of Peripheral Nerve Injuries, with nearly 1.7 million in 2023.
• Among EU4 and the UK, Italy accounted for the highest number of cases of Peripheral Nerve Injuries, followed by France, whereas Spain occupied the bottom of the ladder.
• The number of Upper extremities injuries are higher than that of Lower extremities injuries. In the US, in 2023, the former accounted for nearly 1.2 million, while the latter accounted for nearly 0.5 million.
• In the 7MM, the US accounted for the highest number surgeries Peripheral Nerve Injuries, with nearly 770 thousand in 2023.
• The leading Peripheral Nerve Injury Companies such as Neuraptive Therapeutics, Klisbio, Orthocell limited, Ono pharmaceutical and others.
• Promising Peripheral Nerve Injury Therapies such as NTX-001, Lidocaine, Pregabalin, GW856553, QUTENZA, GRC 17356, SB681323, and others.

Explore Peripheral Nerve Injury Treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injury Epidemiology Segmentation in the 7MM
• Peripheral Nerve Injury Annual Cases
• Annual number of Peripheral Nerve Injury by Extremities
• Total number of Peripheral Nerve Injury surgeries

Download the report to understand which factors are driving Peripheral Nerve Injury Epidemiology trends @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injury Marketed Drugs
• Avance Nerve Graft: Axogen Corporation
Avance Nerve Graft is an off-the-shelf processed human nerve allograft intended for the surgical repair of peripheral nerve discontinuities. Through a proprietary cleansing process for recovered human peripheral nerve tissue, the graft preserves the essential inherent structure of the extracellular matrix (ECM) while cleansing away cellular and noncellular debris. It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. It is processed and distributed by the US FDA and EU requirements for Human Cellular and Tissue-based Products. It had also received Regenerative Medicine Advanced Therapy (RMAT) Designation in 2018, and the company is also conducting a phase III clinical trial, ECON Study, to support its Biologic License Application (BLA) Submission. With the final subject enrolled in July 2020, the last patient is expected to complete the study no later than October of 2021. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.

• Nerbridge: Toyobo
Nerbridge is a resorbable, artificial nerve conduit with polyglycolic acid tubing and a collagenous interior. It is the only such device currently approved in Japan. Nerbridge is mainly used in clinical practice to bridge peripheral nerves after traumatic nerve injury, but there are few reports on its application in reconstruction and repair of the facial nerve. In a study, the utility of Nerbridge to promote nerve regeneration has been evaluated in a murine model of injury to the buccal branch of the facial nerve. The use of Nerbridge has been reported mainly in orthopedic surgery, and its efficacy in trials was 82.8%. The ccompany reports two cases of lingual nerve reconstruction using Nerbridge. In both cases, the lingual nerve was resected due to submandibular gland cancer. The company evaluated the cases by the Semmes-Weinstein monofilaments test. There are problems with length restriction and price, but it is one of the effective reconstruction methods for the reconstruction of the lingual nerve.

Peripheral Nerve Injury Emerging Drugs
• NTX-001: Neuraptive Therapeutics
NTX-001 is a kit used during surgical nerve repairs after trauma or during face and body reconstructive procedures. It is (comprised of previously approved components) provided as sterile solutions. The active pharmaceutical agent is a topically administered product used in conjunction with a delivery device directly to the nerve. The therapy has been extensively studied in preclinical studies, and early clinical cases support advancing into the mid-stage clinical studies. NTX-001 is a potentially transformative adjunctive treatment for peripheral nerve injuries, using a propriety system for the reconnection of severed nerves. Neuraptive Therapeutics is also investigating other therapies for nerve repair. NTX-002 is a device that is under investigation in the preclinical phase as a nerve repair device.

• SilkBridge: KLISBio
SilkBridge consists of a silk fibroin (SF) scaffold with a hybrid electrospun-textile structure in which electrospun (ES) layers, in the inner and outer parts of the device, are coupled to the textile (TEX) layer, in the middle. This configuration allows the body's natural healing process to repair the nerve while its tube shape isolates and protects the injured nerves during the healing process. Silk fibroin is fully biocompatible and promotes cell proliferation by stimulating in vivo tissue regeneration. SilkBridge has an optimized balance of biomechanical and biological properties, can sustain perfect cellular colonization of the conduit and the progressive growth of the regenerating nerve fibers.

Get In-Depth Knowledge on Peripheral Nerve Injury Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Peripheral Nerve Injury Companies
Neuraptive Therapeutics, Klisbio, Orthocell limited, Ono pharmaceutical and others.

Peripheral Nerve Injury Market Outlook
Nerve injuries can result in discomfort and various issues related to muscle innervation or loss of sensation. People of all ages are susceptible to peripheral nerve injuries (PNIs), which can stem from diverse causes such as medical conditions or trauma. PNIs predominantly affect the upper limbs and are often associated with trauma, leading to symptoms like paraesthesia, weakness, paralysis, and pain. Surgical intervention is often necessary for severe nerve damage, with the treatment approach depending on the type of nerve injury. The primary aim of repair is to restore sensory, motor, and autonomic function by regenerating axons, although current therapeutic options may not guarantee complete recovery in all cases.

Peripheral Nerve Injury Drugs Uptake
This section focuses on the rate of uptake of the potential drugs/devices expected to be launched in the market during the study period. The analysis covers Peripheral Nerve Injuries market uptake by drugs/devices; patient uptake by therapies; and sales of each product.

Get In-Depth Knowledge on Peripheral Nerve Injury Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Peripheral Nerve Injury Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Peripheral Nerve Injury Companies- Neuraptive Therapeutics, Klisbio, Orthocell limited, Ono pharmaceutical and others.
• Peripheral Nerve Injury Therapies- NTX-001, Lidocaine, Pregabalin, GW856553, QUTENZA, GRC 17356, SB681323, and others.
• Peripheral Nerve Injury Therapeutic Assessment: Peripheral Nerve Injury Current marketed and Peripheral Nerve Injury emerging therapies
• Peripheral Nerve Injury Market Dynamics: Peripheral Nerve Injury market drivers and Peripheral Nerve Injury market barriers
• Peripheral Nerve Injury Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Peripheral Nerve Injury Unmet Needs, KOL's views, Analyst's views, Peripheral Nerve Injury Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Peripheral Nerve Injury Market Report @

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF PERIPHERAL NERVE INJURIES
4. PERIPHERAL NERVE INJURIES MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
7. PERIPHERAL NERVE INJURIES: DISEASE BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
9. PATIENT JOURNEY
10. MARKETED DRUGS
11. EMERGING TREATMENT
12. PERIPHERAL NERVE INJURIES: MARKET ANALYSIS
13. UNMET NEEDS
14. SWOT ANALYSIS
15. MARKET ACCESS AND REIMBURSEMENT
16. KOL VIEWS
17. APPENDIX
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.